Cargando…

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes

SIMPLE SUMMARY: In the current clinical practice, HER2 status is tested in breast and gastroesophageal cancers to select patients eligible for anti-HER2 treatment. However, HER2 is an emerging biomarker in colorectal cancer (CRC), one of the big killers in oncology. The most frequent types of HER2 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ivanova, Mariia, Venetis, Konstantinos, Guerini-Rocco, Elena, Bottiglieri, Luca, Mastropasqua, Mauro Giuseppe, Garrone, Ornella, Fusco, Nicola, Ghidini, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502498/ https://www.ncbi.nlm.nih.gov/pubmed/36143438 http://dx.doi.org/10.3390/life12091403

Ejemplares similares

Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
por: Sajjadi, Elham, et al.
Publicado: (2023)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

Malignancies in Patients with Celiac Disease: Diagnostic Challenges and Molecular Advances
por: Ivanova, Mariia, et al.
Publicado: (2023)

Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
por: Porta, Francesca Maria, et al.
Publicado: (2023)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
por: Sajjadi, Elham, et al.
Publicado: (2021)

Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling
por: Sajjadi, Elham, et al.
Publicado: (2021)

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
por: Ivanova, Mariia, et al.
Publicado: (2023)

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
por: Pagni, Fabio, et al.
Publicado: (2019)

Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?
por: Sajjadi, Elham, et al.
Publicado: (2020)

Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages
por: Sajjadi, Elham, et al.
Publicado: (2022)

The molecular landscape of breast mucoepidermoid carcinoma
por: Venetis, Konstantinos, et al.
Publicado: (2023)

Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis
por: Sajjadi, Elham, et al.
Publicado: (2023)

PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
por: Fusco, Nicola, et al.
Publicado: (2020)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2023)

Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
por: Venetis, Konstantinos, et al.
Publicado: (2021)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers
por: Venetis, Konstantinos, et al.
Publicado: (2020)

Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
por: Invernizzi, Marco, et al.
Publicado: (2020)

Standard operating procedures for biobank in oncology
por: Bonizzi, Giuseppina, et al.
Publicado: (2022)

Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario
por: Trevisani, Francesco, et al.
Publicado: (2022)

Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
por: Pescia, Carlo, et al.
Publicado: (2023)

Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response
por: Gambini, Donatella, et al.
Publicado: (2022)

Thrombotic Events during Lenvatinib Treatment: A Single Institution Experience
por: Denaro, Nerina, et al.
Publicado: (2022)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies
por: Grizzi, Giulia, et al.
Publicado: (2023)

Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis
por: Tomasello, G., et al.
Publicado: (2022)

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management
por: Venetis, Konstantinos, et al.
Publicado: (2021)

Metastatic Tumors of the Oro-Facial Tissues: Clear Cell Renal Cell Carcinoma. A Clinico-Pathological and Immunohistochemical Study of Seven Cases
por: Capodiferro, Saverio, et al.
Publicado: (2020)

How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review
por: Merlano, Marco Carlo, et al.
Publicado: (2022)

Correlation between Olive Oil Intake and Gut Microbiota in Colorectal Cancer Prevention
por: Memmola, Raffaella, et al.
Publicado: (2022)

Spatially Resolved Molecular Approaches for the Characterisation of Non-Invasive Follicular Tumours with Papillary-like Features (NIFTPs)
por: Piga, Isabella, et al.
Publicado: (2023)

Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles
por: Sajjadi, Elham, et al.
Publicado: (2022)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021)

The Tumor Microenvironment and the Estrogen Loop in Thyroid Cancer
por: Denaro, Nerina, et al.
Publicado: (2023)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

Special Issue: Molecular Biomarkers in Solid Tumors
por: Fusco, Nicola, et al.
Publicado: (2021)

Scheme for a Pathological Index
por: Howden, James C.
Publicado: (1891)

Cannot write session to /tmp/vufind_sessions/sess_iilmr8d5pnchlm9udeck4v3lpl